160280-68-2

Upstream product

• 100-44-7 benzyl chloride 
• 160280-63-7 Methanesulfonic acid (R)-1-[(4R,5R)-2,2-dimethyl-5-((E)-tetradec-1-enyl)-[1,3]dioxolan-4-yl]-2-trityloxy-ethyl ester 
• 160280-64-8 Methanesulfonic acid (E)-(1R,2R,3R)-2,3-dihydroxy-1-hydroxymethyl-heptadec-4-enyl ester 
• 160280-66-0 (2S,3S,4R)-2-azido-1-(trityloxy)octadecane-3,4-diol 
• 160280-65-9 (2R,3R,4R)-1,3,4-trihydroxyoctadecan-2-yl methanesulfonate 
• 117168-59-9 (2S,3S,4R)-2-azido-1,3,4-octadecanetriol 
• 160280-67-1 (2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-trityl-1,3,4-octadecanetriol 

Downstream Products

• 160280-69-3 (2S,3S,4R)-3,4-di-O-benzyl-N-hexacosanoyl-1-O-trityl-2-amino-3,4-octadecanetriol 
• 160280-70-6 (2S,3S,4R)-2-hexacosylamino-3,4-di-O-benzyl-1,3,4-octadecanetriol 

Relevant academic research and scientific papers

Practical Total Synthesis of (2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4- octadecanetriol, the Antitumorial and Immunostimulatory α-Galactosylceramide, KRN7000

A practical total synthesis of (2S,3S,4A)-1-O-(α-D-galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4- octadecanetriol (KRN7000), an antitumorial and immunostimulatory glycosphingolipid derived from agelasphins, was achieved in 14 steps starting from D-lyxose in a 16% overall yield.

HEPATITIS C VIRUS INHIBITOR COMPRISING ALPHA-GLYCOSYLCERAMIDE AS THE ACTIVE INGREDIENT

This invention provides a growth inhibitor of human hepatitis C virus comprising, as an active ingredient, α-glycosylceramide used for patients infected with the aforementioned viruses. This inhibitor of hepatitis C virus comprises, as an active ingredien